Abstract:The small GTPase cycles between the inactive GDP form and the activated GTP form, catalyzed by the upstream guanine exchange factors. The modulation of such process by small molecules has been proven to be a fruitful route for therapeutic intervention to prevent the over-activation of the small GTPase. The fragment based approach emerging in the past decade has demonstrated its paramount potential in the discovery of inhibitors targeting such novel and challenging protein-protein interactions. The details regarding the procedure of NMR fragment screening from scratch have been rarely disclosed comprehensively, thus restricts its wider applications. To achieve a consistent screening applicable to a number of targets, we developed a highly automated protocol to cover every aspect of NMR fragment screening as possible, including the construction of small but diverse libray, determination of the aqueous solubility by NMR, grouping compounds with mutual dispersity to a cocktail, and the automated processing and visualization of the ligand based screening spectra. We exemplified our streamlined screening in RhoA alone and the complex of the small GTPase RhoA and its upstream guanine exchange factor LARG. Two hits were confirmed from the primary screening in cocktail and secondary screening over individual hits for LARG/RhoA complex, while one of them was also identified from the screening for RhoA alone. HSQC titration of the two hits over RhoA and LARG alone, respectively, identified one compound binding to RhoA.GDP at a 0.11 mM affinity, and perturbed the residues at the switch II region of RhoA. This hit blocked the formation of the LARG/RhoA complex, validated by the native gel electrophoresis, and the titration of RhoA to ¹⁵N labeled LARG in the absence and presence the compound, respectively. It therefore provides us a starting point toward a more potent inhibitor to RhoA activation catalyzed by LARG.

Early-stage structure-based drug discovery for small GTPases by NMR spectroscopy

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

Discovery and characterization of small molecules that target the GTPase Ral

Advances in the Development of Rho GTPase Inhibitors

Drugging Ras Gtpase: A Comprehensive Mechanistic And Signaling Structural View

Drugging Ras GTPase: a Comprehensive Mechanistic and Signaling Structural View.

Automated NMR Fragment Based Screening Identified a Novel Interface Blocker to the LARG/RhoA Complex

A Pan-GTPase Inhibitor as a Molecular Probe

Small GTPases: Structure, biological function and its interaction with nanoparticles

Structural Insights into the Regulation Mechanism of Small GTPases by GEFs

Combining NMR and molecular dynamics studies for insights into the allostery of small GTPase-protein interactions.

Discovery and Characterization of Small Molecules That Target the Ral GTPase

Conformational Dynamics in GPCR Signaling by NMR

GPCR structural characterization by NMR spectroscopy in solution

Structure-based drug design: NMR-based approach for ligand-protein interactions.

NMR Characterization of Weak Interactions Between RhoGDI2 and Fragment Screening Hits

Extending the Lifetime of Native GTP‐Bound Ras for Site‐Resolved NMR Measurements: Quantifying the Allosteric Dynamics

Developing Small Molecules that Inhibit K-Ras/GTP Binding Based on New Affinity Measurements

Unveiling the "invisible" druggable conformations of GDP-bound inactive Ras

Targeting Ras-, Rho-, and Rab-family GTPases via a conserved cryptic pocket

Unveiling the "invisible" druggable conformations of GDP-bound inactive Ras.